Bell David S H
Southside Endocrinology, Birmingham, AL 35205, USA.
South Med J. 2008 Nov;101(11):1157-8. doi: 10.1097/SMJ.0b013e3181831441.
Beta blockade is associated with the onset and progression of Peyronie disease (PD). To date, there has not been a report of PD occurring with the alpha/beta blocker carvedilol. It remains unproven but likely that carvedilol was the cause of the PD in the patient described in this case. It is hypothesized that because of carvedilol's vasodilating alpha adrenergic receptor stimulation and its anti-inflammatory effect, PD occurs less frequently with carvedilol than with other beta blockers. However, in this case the protective properties of carvedilol, like vasodilation and the anti-inflammatory effect, may not be sufficient to overcome its vasoconstricting beta adrenergic receptor blockade.
β受体阻滞剂与佩罗尼氏病(PD)的发生和进展有关。迄今为止,尚未有关于使用α/β受体阻滞剂卡维地洛发生PD的报告。卡维地洛是否是本病例中患者PD的病因仍未得到证实,但有可能是其导致的。据推测,由于卡维地洛对α肾上腺素能受体的刺激具有血管舒张作用及其抗炎作用,与其他β受体阻滞剂相比,使用卡维地洛发生PD的频率较低。然而,在本病例中,卡维地洛的保护特性,如血管舒张和抗炎作用,可能不足以克服其对β肾上腺素能受体的血管收缩阻滞作用。